REDUCED MORBIDITY FROM SKELETAL METASTASES IN BREAST CANCER PATIENTS DURING LONG-TERM BISPHOSPHONATE (APD) TREATMENT
- 31 October 1987
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 330 (8566), 983-985
- https://doi.org/10.1016/s0140-6736(87)92555-4
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chlorideAmerican Journal Of Medicine, 1987
- Efficacious Management with Aminobisphosphonate (APD) in Paget??s Disease of BonePublished by Ovid Technologies (Wolters Kluwer Health) ,1987
- Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and biphosphonate treatmentEuropean Journal of Cancer and Clinical Oncology, 1986
- DIPHOSPHONATES FOR OSTEOLYTIC METASTASESThe Lancet, 1985
- COMPARISON OF INTRAVENOUS (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE AND VOLUME REPLETION IN TUMOUR-INDUCED HYPERCALCAEMIAThe Lancet, 1983
- Use of Dichloromethylene Diphosphonate in Metastatic Bone DiseaseNew England Journal of Medicine, 1983
- Comparative study of available medical therapy for hypercalcemia of malignancyAmerican Journal Of Medicine, 1983
- Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeletonAmerican Journal Of Medicine, 1983
- LONG-TERM CONTROLLED TRIAL WITH DIPHOSPHONATE IN PATIENTS WITH OSTEOLYTIC BONE METASTASESThe Lancet, 1983
- Assessment of response to therapy in advanced breast cancer: A project of the Programme on Clinical Oncology of the International Union against Cancer, Geneva, SwitzerlandEuropean Journal of Cancer (1965), 1977